Gut

Article	Citations
Unusual history of ‘stitch’	2211
Response to McAlindon’s letter	1336
Innumerable nodules in all parts of the small intestine	612
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus	518
Correction: P97 A patient information bundle outlining dietary advice in liver disease specific to the cost of living crisis improves patient care: ‘Looking after Your Liver for	343
Real-world evidence supports earlier treatment in HBeAg-positive but not HBeAg-negative chronic hepatitis B virus infection	339
Refining intergenerational MASLD risk: are measurement and mediation shaping the signal?	322
Picking up microbial clues in early-onset colorectal cancer	282
Reassessing the prophylactic effect of clip closure to prevent delayed rebleeding after colorectal endoscopic submucosal dissection	270
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials	261
Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology	245
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	240
IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells	237
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study	223
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?	217
Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system	194
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation	177
Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm	171
Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening	153
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	148
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study	148
Crohn’s disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset	146
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	144
Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction	143
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B	143

S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	142
Where are we with gastric cancer screening in Europe in 2024?	140
Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?	138
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	134
Rare cause of obstructive jaundice	133
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges	133
Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure	132
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment	132
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house?	132
Limitations of Helicobacter pylori single-method testing: evidence from a cohort study	128
Correction: Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	127
Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19	124
Impact of climate change on vulnerable populations	123
Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures	122
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma	120
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research	119
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer	115
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression	110
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?	110
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study	106
Decoding HBV-specific adaptive immunity: from natural clearance to cure	103
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies	101
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma	97
Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling	95
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance	93
Perplexing case of abdominal pain with eosinophilia and fasciitis	92
Unveiling 8 years of duodenoscope contamination: insights from a retrospective analysis in a large tertiary care hospital	92
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy	91
Association between appendectomy and Parkinson’s disease from the UK Biobank	89
Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy	88
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities	86
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD	83
Quantifying artificial sweeteners and emulsifiers in Crohn’s disease and its relationship with disease activity: the ENIGMA study – a novel and targeted approach	83
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	82
Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?	81
Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditio	81
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T H 17 pathogenicity and transdifferentiation	81
A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis	80
Serum creatinine as both yardstick and predictor: reading chronic kidney disease in the global CLEARED cohort	80
SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways	79
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?	79
Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8 + T cells	78
Does the benefit of haemostatic powder differ by Forrest classification in non-variceal upper gastrointestinal bleeding?	78
Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?	78
GI highlights from the literature	77
Correction: Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis	75
Correction: Revisiting the role of sphincterotomy in sphincter of oddi disorder: a critical appraisal of the RESPOnD study	74
British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance	73
APCmosaicism, not always isolated: two first-degree relatives with apparently distinctAPCmosaicism	73
Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B	72

Offspring MASLD risk and the shared familial metabolic milieu: beyond intrauterine explanation	72
Gut microbe alleviates stress-related cancer metastasis by oleic acid degradation	71
Anticoagulation in colorectal ESD: implications for bleeding risk management	69
Blocking MOXD1-derived ACOX1 peroxisome trafficking suppresses metabolic dysfunction-associated steatohepatitis	69
Association between inflammatory bowel disease and Alzheimer’s disease: multivariable and bidirectional Mendelian randomisation analyses	69
Gut-peritoneal-multisystem axis in endometriosis	68
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine	67
Postprandial symptoms in disorders of gut-brain interaction and their potential as a treatment target	67
Rethinking routine mapping biopsies in gastric intestinal metaplasia: justification for endoscopic stratification	67
Environmental and healthcare trade-offs between single-use and reusable gastroscopes	67
Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity	67
Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis	66
Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis	66
Fasting-mimicking diet-enriched Bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8 +	65
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial	65
Response letter to the editor	64
Quest for HBV functional cure: what have we learnt from silencing RNAs?	63
GI highlights from the literature	63
Fatal intestinal disease: a case of recurrent lower gastrointestinal bleeding	62
It takes two to TAM-go	62
Unravelling the obesity paradox in MASLD patients with extrahepatic cancer	61
GI highlights from the literature	61
MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer	60
Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B	60
Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut–brain interaction	60
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma	60
GI highlights from the literature	60
A black liver	59
Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor	59
Understanding the malignant potential of gastric metaplasia of the oesophagus and its relevance to Barrett’s oesophagus surveillance: individual-level data analysis	59
Clarifying the stopping rule and clinical value of AI-guided PEG titration for bowel preparation	58
Non-invasive assessment of MASH resolution	58
Correction: Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn’s Disease	57
Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients	56
Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block	56
Ustekinumab for fistulising perianal Crohn’s disease: a randomised placebo-controlled trial from the GETAID	55
Submucosal steroid pre-injection strategy to prevent oesophageal stricture after circumferential endoscopic submucosal dissection	55
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study	54
In memoriam: Pelayo Correa, MD (1927–2025)	53
Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis	53
Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers	52
Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and	52
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy	52
NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression	52
Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis	51
Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality	51
Correction: PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres	50
Risk of metachronous advanced neoplasia in patients with serrated lesions depending on follow-up schedule	50
Correction: Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway	49
From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions	48
Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU	48
Diagnostic dilemma: a patient with diarrhoea	48
Dominant-negative effect of lactase missense variants: hetero-complex assembly with the wild-type enzyme impairs intracellular trafficking and digestive function	48
Time-varying dynamics of hepatic steatosis and cardiometabolic risk: implications for posthepatitis C cure HCC risk	47
Interplay between diet, circulating indolepropionate concentrations and cardiometabolic health in US populations	46
Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity	46
Human enteric nervous system progenitor transplantation improves functional responses in Hirschsprung disease patient-derived tissue	46
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines	46
ISG15–CREB1 ISGylation: a stellate cell brake in liver fibrosis	46
The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells	45
APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer	45
Combining epigenetic modulation: the next step for HCC immunotherapy?	45
NNMT enriches for AQP5 + cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma	45
Fungi and cancer	45
Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD	44
Simple and dynamic endoscope tip traction to facilitate gastric ESD in difficult locations	44
Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma	44
Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis	44
Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy	44
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated st	43
Assessment of the yearly carbon emission of a gastrointestinal endoscopy unit	43
Landscape of the gut mycobiome dynamics during pregnancy and its relationship with host metabolism and pregnancy health	43
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD	42
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2	41
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989	41
Human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and	41
Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis	40
Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections	40
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis	40
Is HBx protein the X factor in the pathogenesis of IBD?	40

SDC1 + CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers	40
Sex-based differences in prescribed medications, surgical procedures and disease-related complications in IBD	39
GI snapshot: arrhythmia, dysphagia and weight loss in a 71-year-old man	39
Universal ESD for Barrett’s neoplasia: the T1b ‘“limbo’” and risk of overtreatment	39
Correction: Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma	39
Alcohol exhibits contrasting effects on CD8 + T cells in the gut and liver in alcohol-associated liver disease	39
Gut microbiome and dietary fibre intake strongly associate with IgG function and maturation following SARS-CoV-2 mRNA vaccination	39
GI highlights from the literature	39
SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis	39
Real-world treatment patterns in microscopic colitis: a nationwide study from Sweden	38
Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)	38
Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn’s disease	38
Correction: O4 Acceptability and feasibility of a multimodal early detection pilot study for liver disease in high risk groups: “Alright My Liver?”	38
Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease	38
Is the significant risk of perioperative complications associated with radical surgery following non-curative endoscopic submucosal dissection for early colorectal cancer still acceptable?	38
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial	38
Basal levels of microbiota-driven subclinical inflammation are associated with anastomotic leak in patients with colorectal cancer	37
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro	37
Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia	37
DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer	37
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists	36
Vessel and tissue recognition during third-space endoscopy using a deep learning algorithm	36
CD48 is a novel immune checkpoint on tumour‐associated macrophages in hepatocellular carcinoma	36
Trends and cross-country inequality in the incidence of GI cancers among the working-age population from 1990 to 2021: a Global Burden of Disease 2021 analysis	36
Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier fami	35
Rise of precision medicine: can it deliver on its promise in IBD?	35
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study	35
PDE5A + cancer-associated fibroblasts enhance immune suppression in gastric cancer	35
Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis	35
Eosinophils: a novel therapeutic target to promote liver regeneration in acute liver injury?	35
Variceal band ligation and carvedilol: together forever, or not?	35
Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC	34
Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial	34
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy	34
Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation	34
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma	34
Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?	34
HBV integrations reshaping genomic structures promote hepatocellular carcinoma	33
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis	32
CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases	32
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications	32
Artificial intelligence applied to ‘omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment	32
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	32
Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study	31
Correction: O11 Utilising peer support workers in hepatitis C screening in emergency departments: a pilot study	31
Ferritin—a promising biomarker in MASLD	31
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives	31
Presenilins: the hidden guardians of gut health in Alzheimer’s disease	31
Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025	31
Reply to Newmanet al‘Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity’	31
More than meets the eye: a strange cause of bowel obstruction and perforation	31
Unusual cause of abdominal pain	31
Purastat post-EMR: unresolved questions from the PURPLE trial	30
Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?	30
Congenital sucrase-isomaltase mutations worsen IBS-linked V15F dysfunction and trafficking	30
Response to the letter to the editor ‘revisiting lipid dysregulation in colorectal cancer: critical appraisal of pro-inflammatory bias and therapeutic implications’	30
An unusual cause of oesophageal stricture	30
Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis	30
CD177+ neutrophils: new drivers of liver regeneration	30
Germline mutations and pancreatic cancer risk in chronic pancreatitis	30
Response to: ‘Differentiating gastroparesis from functional dyspepsia is no longer sufficient’ by O’Grady et al	29
Response to ‘Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?’	29
Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-microbiome study	29
Reconsidering statins in MASLD: beyond cardiovascular protection to multisystem benefit	29
Accuracy of measuring colorectal polyp size in pathology: a prospective study	29
Cutting waste in endoscopy: the roles of professional practice and staffing levels	29
Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease	29
Context matters for SMYD2 in liver disease: from hepatoprotection to tumour immune escape	29
eCura and W-eCura: different scores, different populations, same goal	29
JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1	29
Patient-reported experience of colonoscopy in Italy: a multicentre prospective observational study	29
Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance	29
Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation	28
Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer	28
Hepatocyte guardian: A20 restrains ferroptosis in autoimmune hepatitis	28
CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma	28
Purified oat protein can trigger acute symptoms linked to immune activation in coeliac disease patients but not histological deterioration	28
Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?	28
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease	27
Intravital imaging: dynamic insights into liver immunity in health and disease	27
DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma	27
Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis	27
Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies	27
Genetic and transcriptomic landscape of colonic diverticulosis	27
Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2	26
A patient-driven agenda for liver cirrhosis research	26
GI highlights from the literature	26
Adherent-invasive Escherichia coli in Crohn’s disease: the 25th anniversary	26
Macropinocytosis of neutrophil extracellular trap by gastric cancer cells promotes immune escape and peritoneal metastasis	26
Novel myo -inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis,	26
Gnotobiotic mice housing conditions critically influence the phenotype associated with transfer of faecal microbiota in a context of obesity	26
Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota	26
SPHINX, a Guardian of Wisdom	25
Endothelial RAP1A attenuates sinusoidal capillarisation and liver fibrosis by inhibiting RAF1-mediated Notch activation	25
World Gastroenterology Organisation - Gut commentary series on digestive health and climate change	25